- Home
- BOLT vs IBIO Comparison
BOLT vs IBIO Comparison
Compare BOLT & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLT
- IBIO
- Stock Information
- Founded
- BOLT 2015
- IBIO 2008
- Country
- BOLT United States
- IBIO United States
- Employees
- BOLT N/A
- IBIO N/A
- Industry
- BOLT Biotechnology: Pharmaceutical Preparations
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- BOLT Health Care
- IBIO Health Care
- Exchange
- BOLT Nasdaq
- IBIO Nasdaq
- Market Cap
- BOLT 25.3M
- IBIO 23.4M
- IPO Year
- BOLT 2021
- IBIO N/A
- Fundamental
- Price
- BOLT $0.57
- IBIO $2.30
- Analyst Decision
- BOLT Hold
- IBIO Strong Buy
- Analyst Count
- BOLT 5
- IBIO 2
- Target Price
- BOLT $1.25
- IBIO $4.30
- AVG Volume (30 Days)
- BOLT 126.9K
- IBIO 97.9K
- Earning Date
- BOLT 11-12-2024
- IBIO 11-12-2024
- Dividend Yield
- BOLT N/A
- IBIO N/A
- EPS Growth
- BOLT N/A
- IBIO N/A
- EPS
- BOLT N/A
- IBIO N/A
- Revenue
- BOLT $9,779,000.00
- IBIO $175,000.00
- Revenue This Year
- BOLT $16.30
- IBIO N/A
- Revenue Next Year
- BOLT N/A
- IBIO N/A
- P/E Ratio
- BOLT N/A
- IBIO N/A
- Revenue Growth
- BOLT 35.86
- IBIO 250.00
- 52 Week Low
- BOLT $0.55
- IBIO $0.25
- 52 Week High
- BOLT $1.56
- IBIO $6.20
- Technical
- Relative Strength Index (RSI)
- BOLT 29.99
- IBIO 40.07
- Support Level
- BOLT $0.63
- IBIO $2.40
- Resistance Level
- BOLT $0.69
- IBIO $2.65
- Average True Range (ATR)
- BOLT 0.03
- IBIO 0.21
- MACD
- BOLT -0.01
- IBIO -0.07
- Stochastic Oscillator
- BOLT 3.49
- IBIO 27.49
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.